Cybin Inc. Announces Q2 2025 Financial Results and Business Update Conference Call
Cybin Inc. will host a conference call on November 13, 2025, to discuss its second-quarter financial results and provide updates on its late-stage neuropsychiatry pipeline, including breakthrough-designated psychedelic treatments for major depressive disorder and generalized anxiety disorder.
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) will host a conference call and webcast at 8 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. The announcement comes as the late-stage neuropsychiatry company continues advancing its pipeline of novel mental health treatments through clinical development.
The timing of this financial disclosure is significant as Cybin progresses two key investigational compounds through advanced clinical trials. The company is developing CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for the adjunctive treatment of major depressive disorder. This compound has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over existing therapies for serious conditions.
Additionally, Cybin is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The company maintains a broader research pipeline of investigational compounds focused on 5-HT receptors, positioning itself at the forefront of neuropsychiatry innovation. Investors and stakeholders can access the full press release detailing the upcoming call at https://ibn.fm/BqH38.
This quarterly update holds particular importance given the substantial unmet need in mental healthcare that Cybin aims to address. The company's mission to revolutionize mental healthcare through next-generation treatment options comes at a critical time when traditional approaches often provide insufficient relief for many patients suffering from mental health conditions. Cybin's focus on developing novel drugs that provide effective and durable results represents a potentially transformative approach to treating conditions that affect millions worldwide.
The conference call will provide insights into the company's financial health and operational progress as it advances its clinical programs. For ongoing updates and news relating to CYBN, the company maintains an active newsroom available at https://ibn.fm/CYBN. Founded in 2019, Cybin has established operational presence across Canada, the United States, the United Kingdom, and Ireland, reflecting its global approach to addressing mental health challenges through innovative pharmaceutical development.
The upcoming financial results and business update will be closely watched by investors and industry observers given the promising class-leading data Cybin has generated and the breakthrough designations received for its lead programs. The company's progress in developing psychedelic-inspired treatments represents a significant shift in how mental health conditions might be treated in the future, moving beyond conventional pharmaceutical approaches to address the root causes of these disorders.